Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward

Current Tropical Medicine Reports

Volumn 2, Issue 3, 2015, Pages 181-187

  Sparks, Hayley ^a   Nair, Gayatri ^a   Castellanos Gonzalez, Alejandro ^a   White, A Clinton ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Cryptosporidiosis; Cryptosporidium; Cryptosporidium hominis; Cryptosporidium parvum; Nitazoxanide; Paromomycin

Indexed keywords

ALANYLGLUTAMINE; AZITHROMYCIN; CLARITHROMYCIN; CYCLOSPORIN; NITAZOXANIDE; PAROMOMYCIN; RIFABUTIN; RIFAMYCIN; SPIRAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

COST EFFECTIVENESS ANALYSIS; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; ESCHERICHIA COLI; HUMAN; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPROMISED PATIENT; MALNUTRITION; NONHUMAN; ORAL REHYDRATION THERAPY; PRIORITY JOURNAL; REVIEW;

EID: 84981518734     PISSN: None     EISSN: 21963045     Source Type: Journal    
DOI: 10.1007/s40475-015-0056-9     Document Type: Review

References (66)

1. White Jr AC. Cryptosporidiosis (Cryptosporidium species). In: Mandell D, editor. Bennett’s principals and practices of infectious diseases. Philadelphia: Elsevier Saunders; 2015. p. 3173–83.e6.
2. Checkley W et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2015;15(1):85–94. This state of the art review came from a meeting of most of the leaders in the field to define the state-of-the art, gaps, and future research directions regarding epidemiology, diagnosis, treatment, and vaccination for cryptosporidiosis.
3. Cama VA et al. Cryptosporidium species and subtypes and clinical manifestations in children, Peru. Emerg Infect Dis. 2008;14(10):1567–74.
4. Ryan U, Fayer R, Xiao L. Cryptosporidium species in humans and animals: current understanding and research needs. Parasitology. 2014;141(13):1667–85.
5. Chalmers RM, Katzer F. Looking for Cryptosporidium: the application of advances in detection and diagnosis. Trends Parasitol. 2013;29(5):237–51.
6. Goodgame RW et al. Intestinal function and injury in acquired immunodeficiency syndrome-related cryptosporidiosis. Gastroenterology. 1995;108(4):1075–82.
7. Zhang Y et al. Lactulose-mannitol intestinal permeability test in children with diarrhea caused by rotavirus and cryptosporidium. Diarrhea Working Group, Peru. J Pediatr Gastroenterol Nutr. 2000;31(1):16–21.
8. Pantenburg B et al. Intestinal immune response to human Cryptosporidium sp. infection. Infect Immun. 2008;76(1):23–9.
9. Hernandez J et al. Substance P is responsible for physiological alterations such as increased chloride ion secretion and glucose malabsorption in cryptosporidiosis. Infect Immun. 2007;75(3):1137–43.
10. Scallan E et al. Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis. 2011;17(1):7–15.
11. Painter JE et al. Cryptosporidiosis surveillance—United States, 2011–2012. MMWR Surveill Summ. 2015;64 Suppl 3:1–14.
12. Shirley DA, Moonah SN, Kotloff KL. Burden of disease from cryptosporidiosis. Curr Opin Infect Dis. 2012;25(5):555–63.
13. Kotloff KL et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case–control study. Lancet. 2013;382(9888):209–22. This reports the results of a multicenter study of childhood diarrhea from 7 countries in SubSaharan Africa and South Asia. It highlighted the role of Cryptosporidium as second to rotavirus as a cause of moderate to severe diarrhea and death among children under 2 years of age.
14. Liu J et al. Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study. Lancet Infect Dis. 2014;14(8):716–24. This multicenter study compared multiplex PCR, film array, and bead arrays assays for multiple pathogens. Overall, it demonstrated that each of the techniques was highly reproducible and demonstrated that Cryptosporidium was underdiagnosed even using specimens from the GEMS study.
15. Moore SR et al. Prolonged episodes of acute diarrhea reduce growth and increase risk of persistent diarrhea in children. Gastroenterology. 2010;139(4):1156–64.
16. Guerrant DI et al. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four–seven years later in a poor urban community in northeast Brazil. Am J Trop Med Hyg. 1999;61(5):707–13.
17. Mondal D et al. Contribution of enteric infection, altered intestinal barrier function, and maternal malnutrition to infant malnutrition in Bangladesh. Clin Infect Dis. 2012;54(2):185–92.
18. Molbak K et al. Cryptosporidium infection in infancy as a cause of malnutrition: a community study from Guinea-Bissau, West Africa. Am J Clin Nutr. 1997;65(1):149–52.
19. Guerrant RL et al. The impoverished gut—a triple burden of diarrhoea, stunting and chronic disease. Nat Rev Gastroenterol Hepatol. 2013;10(4):220–9.
20. Costa LB et al. Cryptosporidium-malnutrition interactions: mucosal disruption, cytokines, and TLR signaling in a weaned murine model. J Parasitol. 2011;97(6):1113–20.
21. Checkley W et al. Effects of Cryptosporidium parvum infection in Peruvian children: growth faltering and subsequent catch-up growth. Am J Epidemiol. 1998;148(5):497–506.
22. Cabada MM, White Jr AC. Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis. 2010;23(5):494–9.
23. Masur H et al. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(9):1308–11.
24. Dillingham RA et al. High early mortality in patients with chronic acquired immunodeficiency syndrome diarrhea initiating antiretroviral therapy in Haiti: a case–control study. Am J Trop Med Hyg. 2009;80(6):1060–4.
25. Mele R et al. Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. Int J Parasitol. 2003;33(7):757–64.
26. Amadi B et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet. 2002;360(9343):1375–80.
27. Rossignol JF et al. Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin Gastroenterol Hepatol. 2006;4(3):320–4.
28. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J Infect Dis. 2001;184(1):103–6.
29. Amadi B et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect Dis. 2009;9:195.
30. Hussien SM et al. Comparative study between the effect of nitazoxanide and paromomycine in treatment of cryptosporidiosis in hospitalized children. J Egypt Soc Parasitol. 2013;43(2):463–70.
31. Raja K et al. Prevalence of cryptosporidiosis in renal transplant recipients presenting with acute diarrhea at a single center in Pakistan. J Nephropathol. 2014;3(4):127–31.
32. Danziger-Isakov L. Gastrointestinal infections after transplantation. Curr Opin Gastroenterol. 2014;30(1):40–6.
33. Bhadauria D et al. Cryptosporidium infection after renal transplantation in an endemic area. Transpl Infect Dis. 2015;17(1):48–55.
34. Legrand F et al. Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study. Bone Marrow Transplant. 2011;46(6):858–62.
35. Bonatti H et al. Cryptosporidium enteritis in solid organ transplant recipients: multicenter retrospective evaluation of 10 cases reveals an association with elevated tacrolimus concentrations. Transpl Infect Dis. 2012;14(6):635–48.
36. Krause I et al. Cryptosporidiosis in children following solid organ transplantation. Pediatr Infect Dis J. 2012;31(11):1135–8.
37. Fan X et al. CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome. Clin Immunol. 2012;143(2):152–61.
38. Hashmey R et al. Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine (Baltimore). 1997;76(2):118–39.
39. Hewitt RG et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin Infect Dis. 2000;31(4):1084–92.
40. White Jr AC et al. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J Infect Dis. 1994;170(2):419–24.
41. Allam AF, Shehab AY. Efficacy of azithromycin, praziquantel and mirazid in treatment of cryptosporidiosis in school children. J Egypt Soc Parasitol. 2002;32(3):969–78.
42. Smith NH et al. Combination drug therapy for cryptosporidiosis in AIDS. J Infect Dis. 1998;178(3):900–3.
43. Giacometti A et al. Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. J Antimicrob Chemother. 2000;45(4):453–6.
44. Holmberg SD et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. JAMA. 1998;279(5):384–6.
45. Fichtenbaum CJ et al. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS. 2000;14(18):2889–93.
46. Amenta M et al. Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. J Chemother. 1999;11(5):391–5.
47. Gathe Jr JC et al. Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS. J Acquir Immune Defic Syndr. 2008;48(3):363–4.
48. Kothavade RJ. Challenges in understanding the immunopathogenesis of Cryptosporidium infections in humans. Eur J Clin Microbiol Infect Dis. 2011;30(12):1461–72.
49. Feng H et al. Bile acids enhance invasiveness of Cryptosporidium spp. into cultured cells. Infect Immun. 2006;74(6):3342–6.
50. Yang YL, Buck GA, Widmer G. Cell sorting-assisted microarray profiling of host cell response to Cryptosporidium parvum infection. Infect Immun. 2010;78(3):1040–8.
51. Castellanos-Gonzalez A et al. Human primary intestinal epithelial cells as an improved in vitro model for Cryptosporidium parvum infection. Infect Immun. 2013;81(6):1996–2001.
52. Murphy RC et al. Discovery of potent and selective inhibitors of calcium-dependent protein kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett. 2010;1(7):331–5.
53. Castellanos-Gonzalez A et al. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. J Infect Dis. 2013;208(8):1342–8.
54. Na BK et al. Cryptopain-1, a cysteine protease of Cryptosporidium parvum, does not require the pro-domain for folding. Parasitology. 2009;136(2):149–57.
55. Ndao M et al. A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection. Antimicrob Agents Chemother. 2013;57(12):6063–73.
56. Kumar VP et al. Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase. Bioorg Med Chem Lett. 2014;24(17):4158–61.
57. Sun Z et al. Synthesis, in vitro evaluation and cocrystal structure of 4-oxo-[1]benzopyrano[4,3-c]pyrazole Cryptosporidium parvum inosine 5′-monophosphate dehydrogenase (CpIMPDH) inhibitors. J Med Chem. 2014;57(24):10544–50.
58. Gorla SK et al. Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. Antimicrob Agents Chemother. 2014;58(3):1603–14.
59. Jefferies R et al. Target validation of the inosine monophosphate dehydrogenase (IMPDH) gene in Cryptosporidium using Phylomer((R)) peptides. Exp Parasitol. 2015;148:40–8.
60. Bessoff K et al. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth. Antimicrob Agents Chemother. 2013;57(4):1804–14.
61. Spangenberg T et al. The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS One. 2013;8(6), e62906.
62. Bessoff K et al. Identification of Cryptosporidium parvum active chemical series by repurposing the open access malaria box. Antimicrob Agents Chemother. 2014;58(5):2731–9.
63. Debnath A, Ndao M, Reed SL. Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases. Gut Microbes. 2013;4(1):66–71.
64. Castro IC et al. Arginine decreases Cryptosporidium parvum infection in undernourished suckling mice involving nitric oxide synthase and arginase. Nutrition. 2012;28(6):678–85.
65. Costa LB et al. Novel in vitro and in vivo models and potential new therapeutics to break the vicious cycle of Cryptosporidium infection and malnutrition. J Infect Dis. 2012;205(9):1464–71.
66. Kandil HM, Berschneider HM, Argenzio RA. Tumour necrosis factor alpha changes porcine intestinal ion transport through a paracrine mechanism involving prostaglandins. Gut. 1994;35(7):934–40.